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Iris melanomas are less likely to metastasize than pos-
terior compartment melanomas. The anterior chamber
of the eye is an immunosuppressed microenvironment
where a wide range of immunosuppressive factors in
aqueous humor contribute to the immune privilege.
One such factor is a-melanocyte-stimulating hormone,
a potent anti-in£ammatory neuropeptide that exhibits
e⁄cacy in many studies of acute and chronic in£am-
mation. The aim of this study was to investigate
whether the di¡erent metastatic behavior of iris mela-
nomas versus posterior compartment melanomas might
be explained by the di¡ering immunosuppressive/anti-
in£ammatory environments of these tumors in vivo.
To investigate this hypothesis, we studied the e¡ect of
human aqueous and vitreous £uids, of the proin£am-
matory cytokine tumor necrosis factor a, and of the
anti-in£ammatory peptides a-melanocyte-stimulating
hormone and melanocyte-stimulating hormone 11^13
(KP-D-V) on the invasion of three human uveal mela-
noma cell lines through human ¢bronectin. Fresh aqu-
eous humor samples signi¢cantly decreased the invasion
in two out of three uveal melanoma cell lines. In con-
trast, vitreous humor did not reduce invasion. Tumor
necrosis factor a signi¢cantly increased the invasiveness
of uveal melanoma cell lines by approximately 50%^
80% over 20 h. Full-length a-melanocyte-stimulating
hormone, at concentrations present in the aqueous
humor (109 M), as well as melanocyte-stimulating
hormone 11^13 (KP-D-V) reduced the invasion of cells
through human ¢bronectin by 45%^50% and also pro-
tected uveal melanoma cells from the pro-invasive
actions of tumor necrosis factor a. These data are consis-
tent with in£ammation playing a major role in a¡ect-
ing the metastatic ability of uveal melanomas. Thus,
ocular microenvironments that di¡er in their immuno-
suppressive/anti-in£ammatory properties may in£uence
the invasiveness of developing tumors. Key words:
aqueous humor/vitreous humor/melanoma/melano cortin/TNF-a/
a-MSH. J Invest Dermatol 121:557 ^563, 2003
U
veal melanoma is the most common primary in-
traocular malignant tumor in adults. In contrast to
cutaneous melanoma and due to the lack of lym-
phatics in the eye, uveal melanomas spread via
hematogenous dissemination, preferentially targeting
the liver (Mooy and De Jong, 1996). Even after enucleation or ir-
radiation, metastases from this malignancy appear in a large
number of patients (Egan et al, 1998). The life expectancy of pa-
tients with metastasis is generally less than 1 y and the median
survival for patients diagnosed with hepatic metastasis is extre-
mely poor, between 2 and 6 mo (Rajpal et al, 1983). Once metas-
tases have occurred, little e¡ective therapy is available. Thus, the
development of new and reliable prognostic indicators to detect
metastatic disease is an important goal, together with an im-
proved understanding of what factors may in£uence metastatic
spread. Advances in these areas may then contribute to the
development of new approaches to the prevention and treatment
of metastatic disease.
Despite the fact that melanomas can arise anywhere in the
uveal tract, they most commonly occur in the posterior compart-
ment of the eye (Hogan and Zimmerman, 1962). Anterior cham-
ber and posterior compartment melanoma tumors have very
similar cytologic and morphologic features (Grossniklaus et al,
1995a). It is well established that patients with primary uveal tu-
mors of the iris have a better prognosis than those with tumors
of the posterior uvea (W˛ll et al, 1999). There have been a number
of suggestions to explain this phenomenon such as the smaller
size of iridial tumors, vascular di¡erences, the time of clinical re-
cognition, and microenvironmental di¡erences in the host im-
mune response (Grossniklaus et al, 1995b; 1996; W˛ll et al, 1999;
Singh et al, 2001).
This study focuses on the immune privilege of the anterior
versus the posterior compartment. The eye is unique in having a
local immune defense system organized anatomically and at the
level of the microenvironment. The absence of a lymphatic sys-
tem, a blood^aqueous barrier, and a blood^retinal barrier isolates
the intraocular tissues from the systemic circulation, protecting
the eye from invasion by pathogens and in£ammatory cells. If
Reprint requests to: Professor S. MacNeil, Section of Human Metabo-
lism, Division of Clinical Sciences (North), Northern General Hospital,
She⁄eld S5 7AU, UK
Abbreviations: MC-R, melanocortin receptor; a-MSH, a-melanocyte-
stimulating hormone.
Manuscript received November 19, 2002; revised February 20, 2003;
accepted for publication April 1, 2003
0022-202X/03/$15.00 . Copyrightr 2003 by The Society for Investigative Dermatology, Inc.
557
pathogens or in£ammatory cells invade the eye, however, a strict
regulation of the local defense is needed. In this way, the immune
privilege prevents potential devastating e¡ects of the in£amma-
tory and immune responses to very delicate anatomic structures
within the eye. This unusual intraocular immune deviation has
its basis in a selective antigen-speci¢c de¢ciency of delayed hy-
persensitivity and complement ¢xing antibodies (Streilein, 1999).
Immune privilege in the anterior chamber of the eye has been
demonstrated by the unexpected immunosuppression that results
from the introduction of antigen or immune cells into the ante-
rior chamber of the eye (Cousins et al, 1991a; 1991b; Mo and Strei-
lein, 2001). At the level of this microenvironment, the immune-
mediated in£ammation observed is relatively mild compared
with alternative sites such as the skin for an equivalent in£amma-
tory insult. As yet, there has been little comparative work on how
the di¡ering immunosuppressive/anti-in£ammatory environ-
ments of the anterior and posterior compartments might a¡ect
tumor progression.
The immune system of the anterior chamber can in part be
explained by the production of immunosuppressive factors with-
in the eye and their release into the aqueous humor, which ¢lls
the anterior chamber (Streilein, 1993). Aqueous humor on its own
is capable of inhibiting several antigen-stimulated lymphocyte
activities in vitro, especially proliferation and cytokine production
(Taylor et al, 1994). The immunosuppressive activity of aqueous
humor can be divided biochemically into two inhibitory frac-
tions with di¡ering molecular weights. A substantial component
of this activity is reported to be present in a low molecular
weight fraction below 3500 Da (Streilein and Niederkorn, 1981).
One of the components found in this fraction is the neuropeptide
a-melanocyte-stimulating hormone (a-MSH; Mr¼1665 Da).
This is of particular interest as we have recently identi¢ed it to
be a potent anti-invasive molecule in vitro for cutaneous melano-
ma cells (Zhu et al, 2002).
a-MSH is composed of 13 amino acids and exerts biologic
action on a number of cell types through the melanocortin recep-
tors. To date, ¢ve di¡erent melanocortin receptors have been
cloned (MC-1RMC-5R) (Mountjoy et al, 1992; Chhajlani et al,
1993). a-MSH has highest ligand binding a⁄nity for the MC-1R,
which is expressed on a number of di¡erent cell types, including
cutaneous melanocytes and melanoma cells, endothelial cells, and
keratinocytes (Mountjoy et al, 1992; Hartmeyer et al, 1997). In
recent years, a-MSH has been found to have potent immuno-
suppressive and anti-in£ammatory properties, including the inhi-
bition of interleukin-1b (IL-1b), tumor necrosis factor a (TNF-
a), and IL-6. It has also been reported to inhibit neutrophil mi-
gration and activation and to be involved in inhibition of contact
sensitization (Knisely et al, 1994). Previous work from our group
has reported that a-MSH acts as a potent inhibitor of TNF-a-sti-
mulated activation of nuclear factor kB (NF-kB) and glutathione
peroxidase and upregulation of intercellular adhesion molecule 1
(ICAM-1) in melanocytes (cutaneous and uveal) and melanoma
cells (cutaneous) (Hedley et al, 1998; Haycock et al, 1999; 2000).
More recently, we have found that it also acts to inhibit the ac-
tions of TNF-a in keratinocytes (Moustafa et al, 2002).
The aim of this study was to investigate the hypothesis that the
di¡ering metastatic behavior of iris melanomas versus posterior
compartment melanomas might be explained by the di¡ering
immunosuppressive/anti-in£ammatory environments of these tu-
mors in vivo. To investigate this hypothesis, we studied the e¡ect
of human aqueous and vitreous £uids, of the proin£ammatory
cytokine TNF-a, and of anti-in£ammatory peptides a-MSH
and MSH 11^13 (KP-D-V) on the invasion of human uveal
melanoma cell lines.
MATERIALS AND METHODS
Uveal melanoma cells and culture Three human uveal melanoma cell
lines were used in the study: (1) SOM (She⁄eld Ocular Melanoma) 196b;
(2) 177w7B7; (3) VUP.The SOM196b cell line was derived from a primary
choroidal melanoma. SOM 177w7B7 was derived by transfection of a
primary choroidal melanoma with B7-1 (CD80) cDNA, as described by
Hedley et al (2000). The VUP uveal melanoma cell line was established
from a choroidal melanoma, as described by Siracky et al (1982). The line
was kindly donated by Professor I.R. Hart (Richard Dimbleby
Department of Cancer Research/ICRF Laboratory, St Thomas’ Hospital,
London, UK). SOM 196b and 177w7B7 melanoma cells were maintained
in a humidi¢ed atmosphere at 371C (5% CO2 and 95% air) as adherent
monolayers in RPMI-1640 medium supplemented with 10% (vol/vol)
fetal bovine serum, 20 ng per ml epidermal growth factor (EGF), 100 IU
per ml penicillin, 100 mg per ml streptomycin, 1.2 mg per ml amphotericin
B, and 0.2% (wt/vol) D-glucose. The 177w7B7 line was cultured with
geneticin (0.5 ng per ml) in the culture medium. The VUP uveal
melanoma cell line was maintained as above but cultured in Dulbecco’s
modi¢ed Eagle’s medium supplemented with 10% (vol/vol) fetal bovine
serum, 20 ng per ml EGF, 100 IU per ml penicillin, 100 mg per ml
streptomycin, 1.2 mg per ml amphotericin B, 2 mM L-glutamine, and
0.2% wt/vol D-(þ )-glucose. Cultures were tested for mycoplasma
contamination. In all experiments, cells were detached from tissue culture
£asks using nonenzymatic dissociation solution (Sigma, Poole, Dorset,
UK). Cells for experimentation were used between passage number 25
and 45.
Aqueous and vitreous sample collection Human aqueous and
vitreous samples were collected from patients with primary posterior
uveal melanomas at the time of enucleation. Consent for sample
collection was obtained from the Ethics Committee of the Royal
Hallamshire Hospital Trust (NHS, She⁄eld, UK). Informed consent was
obtained from each patient prior to collection. After collection, samples
were kept at 41C, centrifuged to eliminate possible residual tissue, and
¢ltered through a 0.22 mm pore ¢lter. Samples were used in the
¢bronectin invasion assay at 25% (vol/vol) in serum-free invasion assay
medium (SFIAM; for composition details see below) within 4 h after
enucleation.
Fibronectin invasion assay Nunc 10 mm tissue culture inserts,
containing a polycarbonate ¢lter with 8.0 mm diameter pores randomly
distributed over its surface, were inverted in six-well tissue culture plates;
76 mL of human ¢bronectin at 100 mg per ml was added to the underside of
each polycarbonate ¢lter and left for 1 h at 371C in a 5% CO2/95% air
atmosphere. The inserts were then placed the correct way up and any
excess of ¢bronectin was removed. The six-well plates containing the
inserts were then left to dry uncovered for 30 min in a laminar £ow
hood. Finally, inserts were placed in a 24-well plate containing 500 mL of
SFIAM based on RPMI-1640 medium supplemented with 20 ng per ml
EGF and 0.2% wt/vol D-glucose solution. All cell types used in the study
were removed from the tissue culture £asks, centrifuged at 250g for 5 min,
and resuspended in SFIAM. Cell suspensions (250 mL containing
approximately 1.8105 cells) plus an equivalent volume of SFIAM (with
or without a-MSH/TNF-a/KP-D-V/aqueous/vitreous) were then added to
each insert. a-MSH or KP-D-Vwas added 15 min before addition of TNF-
a to the inserts. Triplicate wells were used in all experiments (except for
those involving aqueous/vitreous £uid where duplicate wells were used
because of lack of £uid). All experiments were repeated on at least three
occasions.
Cells (untreated or treated) were left for 20 h at 371C in a 5% CO2/95%
air atmosphere. The 20 h experimental time was chosen on the basis of
previous time-course experiments showing that su⁄cient cell invasion
had occurred (15%^30%) by this time (Eves et al, 2000). After
examination under the light microscope, all cells were harvested and
medium containing cells was collected from the upper chambers (inserts)
and the lower chambers (wells from the 24-well plate) and replaced with
an equivalent volume of 0.1% wt/vol trypsin and 0.02% wt/vol
ethylenediamine tetraacetic acid (EDTA) to remove remaining cells.
Volumes were calculated by weighing the total contents of the upper and
lower chambers using preweighed tubes. Cell number was determined
using a hemocytometer. Invading cells were counted as those removed
from the underside of the ¢lter, suspended in the medium of the 24-well
plate, or attached to the bottom of the well. Non-invading cells were
counted as those remaining in the insert, either in suspension or attached
to the upper surface of the ¢lter. The percentage of the total number of
cells recovered that had invaded through ¢bronectin over 20 h was then
calculated. This methodology is an improvement on the assay ¢rst
described from this laboratory by Dewhurst et al (1997). Introduction of
weighing to ensure accurate calculation of total cell number recovered
improved the running of this assay and gave percentage recoveries of
80%^110% with SEM of triplicates of less than 5%.
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Identi¢cation of the MC-1R by western blotting T75 cell culture
£asks containing monolayers of cells at 80%^90% con£uence were
washed in phosphate-bu¡ered saline (PBS)/ EDTA (4 mM), and pelleted.
Pellets were placed into 500 mL of a sodium dodecyl sulfate (SDS) lysis
bu¡er (20% wt/vol SDS in PBS supplemented with commercial protease
inhibitors (Bio-Rad)) on ice for 20 min in order to extract total protein.
Protein concentration was measured by the bicinchoninic acid method
(Pierce Laboratories, Rockford, IL). Protein samples were prepared by
boiling in a sample bu¡er (75 mM TrisHCl, pH 6.8, containing 15%
(wt/vol) SDS, 5% (vol/vol) b-mercaptoethanol, 20% (vol/vol) glycerol,
0.001% (wt/vol) bromophenol blue) for 5 min. Fifteen micrograms of
sample protein was loaded per gel track and proteins were separated using
a discontinuous denaturing system (5% acrylamide stacking gel, 10%
acrylamide resolving gel) (200 V, 1 h, Mini-Protean II, Bio-Rad Hemel,
Hempstead, UK) according to the method of Laemmli (1970). After
electrophoretic separation, proteins were transferred onto 0.45 mm
nitrocellulose membrane according to the method of Towbin et al (1979)
(Mini-Protean II TransBlot, Bio-Rad). Unreacted membrane binding sites
were blocked overnight at 41C with 5% (wt/vol) commercial dried milk
powder in TBST bu¡er (10 mM TrisHCl, 0.15 M NaCl, 0.05% (wt/vol)
Tween 20, pH 8.0 (TBST-M)) and then incubated overnight at 41C with
a primary anti-MC-1R goat polyclonal IgG (N-19, Santa Cruz, Santa
Cruz, CA) diluted 1:50 (vol/vol) with TBST-M. Membranes were washed
(315 min, room temperature and pressure) in TBST-M followed by 1 h
incubation with a horseradish-peroxidase-conjugated sheep antigoat
secondary antibody (1:1500 vol/vol in TBST). Membranes were then
washed 315 min (in TBST-M) and once with TBST for 15 min.
Immunoreactive bands were visualized by incubating membranes in
0.05% (wt/vol) 3, 30 -diaminobenzidine hydrochloride/0.09% (vol/vol)
hydrogen peroxide in PBS (5 min).
Statistical analysis Statistical signi¢cance was assessed using Student’s
paired t test on control versus treated samples for a minimum of three
separate experiments (each based on mean values of triplicate (or for
aqueous/vitreous £uids duplicate) wells). All statistics were undertaken on
the values calculated for percentage invasion. Results of several
experiments were then normalized for ease of presentation of the data.
RESULTS
E¡ect of aqueous and vitreous £uids on uveal melanoma
invasion Preliminary experiments using human aqueous and
vitreous samples identi¢ed that biologic activity present in
aqueous £uid was lost by storing samples at 201C for 2 wk.
Subsequently, samples were kept at 41C and all experiments
were conducted within 24 h of obtaining a sample from the
operating theater. Sample volumes collected from aqueous £uids
were rarely greater than 200^250 mL. In order to have duplicates
within each experiment, human aqueous and vitreous samples
were used at 25% (vol/vol) in SFIAM. Table I shows the
percentage invasion obtained for the three cell lines treated with
25% (vol/vol) aqueous, 25% (vol/vol) vitreous, and for untreated
cells (control). Three separate experiments were conducted with
each cell line, in each case using ocular £uids from di¡erent
donors. 25% (vol/vol) aqueous £uid signi¢cantly decreased the
invasion of two of these cell lines to 42.1%75.0% of the
untreated cells for the SOM 196b cell line and to 65.01%75.2%
for theVUP cell line. Results in the third line (177w7B7) showed
a reduction in invasion with aqueous £uid that failed to achieve
statistical signi¢cance. In contrast, treatment with 25% vitreous
humor had no signi¢cant e¡ect on the level of invasion for two
of the lines (196b and VUP) and actually signi¢cantly increased
invasion of the third cell line (177w7B7).
E¡ect of the proin£ammatory cytokine TNF-a on uveal
melanoma invasion The e¡ect of TNF-a (100^300 units per
ml) on the invasion of the three uveal melanoma cell lines was
assessed. After 20 h of incubation, unstimulated cells showed an
average invasion of 27.7%74.1% (based on 19 experiments) for
the SOM 196b cell line, 16.5%71.4% (n¼ 20 experiments)
for the VUP cell line, and 25.8%73.4% (n¼11 experiments) for
the 177w7B7 cell line. TNF-a signi¢cantly increased invasion for
all three cell lines (Fig 1). Results are presented as the mean
percentage of invasion found in the control (normalized to
100%). For two of the lines, the maximum increase in invasion
was seen at 100 units per ml TNF-a with 177.1%þ 18.5% (n¼ 5
experiments) for the VUP cell line and 181.5%þ 27.9% (n¼ 4
experiments) for the 177w7B7 cell line (Fig 1). The 196b cell line
was slightly more resistant to TNF-a with a maximum response
seen at 200 units per ml of 156.6%78.1% (n¼ 4 experiments)
invasion (Fig 1).
Expression of MC-1R in uveal melanoma cell lines Western
immunoblotting using a polyclonal antibody raised against
the MC-1R revealed an immunoreactive band for all three cell
lines investigated, corresponding to a molecular weight of
approximately 37 kDa (see Fig 2). A single additional band was
also seen for each cell line at a slightly higher molecular weight.
It is possible that the two bands correspond to N-glycosylated
and nonglycosylated products of the receptor. Furthermore,
higher molecular weight bands were also observed, thought to
be nonspeci¢c polyclonal cross-reactive sites.
E¡ect of a-MSH on uveal melanoma cell invasion Having
established that the uveal melanoma cells expressed the MC-1R,
Table I. E¡ect of aqueous and vitreous £uids on uveal melanoma invasion
% Invasion
Cell line Experiment Control Aqueous Vitreous
196b 1 16.3371.80 7.8470.04 12.1773.01
2 12.0670.86 5.5870.38 23.0671.38
3 24.2672.37 7.8170.46 19.9174.51
po0.05 n.s.
VUP 1 14.4670.91 10.5071.38 16.5671.13
2 13.0171.76 10.2470.04 15.6270.58
3 17.3371.77 8.3370.99 15.8570.40
po0.05 n.s.
177w7B7 1 13.4271.09 10.7072.52 18.8170.16
2 17.1671.61 11.9074.15 24.9070.41
3 13.1270.53 12.871.13 20.7272.94
n.s. po0.01
The e¡ects of 25% aqueous or vitreous £uids on the ability of three ocular melanoma cell lines to invade through ¢bronectin over 20 h were examined. Three separate
experiments were conducted with each cell line using ocular £uids from di¡erent donors.The overall recovery of cells was calculated as the total number of cells recovered
in the upper and lower chambers expressed as a percentage of the number of cells initially added at the beginning of the experiment (1.8105). For these experiments
recovery ranged from 75%111% with a mean recovery of 95%711%. The table shows percentage invasion based on the number of cells in the lower chamber as a
percentage of the total cell number. Mean recoveries7SEM were calculated from duplicate wells of cells for each experimental group. Student’s paired t test was used to
compare invasion without (control) and with ocular £uids based on three experiments.
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we then looked at the e¡ect of a-MSH on invasion of these cell
lines; results are summarized in Fig 3. The lowest concentration
of a-MSH investigated (1011 M) signi¢cantly decreased invasion
for two of the three cell lines. Maximum inhibition of invasion
was seen at 109 M a-MSH for all cell lines. Overall, this
approximated to a 50% decrease in the level of invasion for all
lines: 49.3%710.1% (n¼ 4) for the 196b cell line; 48.3%712.4%
(n¼ 5) for the VUP cell line; and 45.9%76.9% (n¼ 4) for the
177w7B7 cell line. Interestingly, concentrations of a-MSH at
107 M were no more e¡ective than 109 M in inhibiting
invasion. Indeed, for one of the cell lines (177w7B7) the
inhibition at 107 M was slightly less (72.4%74.9%) than that
seen at 109 M (a biphasic dose^response to the a-MSH peptide,
where a higher concentration of peptide is less e¡ective, has been
reported previously (Lipton and Catania, 1997)).
Comparative potency of a-MSH and MSH 11^13 KP-D-V
peptides on uveal melanoma invasion We next examined a
tripeptide (MSH 11^13 KP-D-V) for anti-invasive potency
compared to the full-length a-MSH peptide, using the cell line
SOM 196b. It was observed that the KP-D-V peptide was as
e¡ective as the full-length a-MSH peptide at inhibiting invasion
through ¢bronectin, over a concentration range of 1011107
M. No signi¢cant di¡erence in potencies between the two
peptides was observed (Fig 4).
Figure1. E¡ect of TNF-a on invasion of three uveal melanoma cell
lines through human ¢bronectin. Triplicate wells of cells were treated
with TNF-a (100^300 units per ml) for 20 h during the ¢bronectin inva-
sion experiment.TNF-a signi¢cantly increased the invasion in all three cell
lines at 200 and 300 units per ml. Results are expressed as a mean percen-
tage of the control7SEM. , SOM 196b (n¼ 4 experiments); ?, 177w7B7
(n¼ 4 experiments); ?,VUP (n¼ 5 experiments). po0.05; po0.01.
Figure 2. Western immunoblotting for the MC-1R. 12.5 mg total cel-
lular protein was loaded per gel track from three uveal melanoma cell lines
(196b, VUP, and 177w7B7, as indicated at the top of each track). M is the
SDS-7B molecular weight marker. A single prominent immunoreactive
band was identi¢ed migrating at approximately 37 kDa (indicated) for each
uveal melanoma cell type.
Figure 3. E¡ect of a-MSH on invasion of three uveal melanoma cell
lines through human ¢bronectin. Triplicate wells of cells were incu-
bated with a-MSH (1011 M107 M) for 20 h during the ¢bronectin in-
vasion experiment. a-MSH signi¢cantly decreased uveal melanoma
invasion levels in all three lines, with maximum inhibition at 109 M for
all lines. Results are expressed as a mean percentage of the control7SEM.
‘, SOM 196b (n¼ 5 experiments); ?, 177w7B7 (n¼ 4 experiments); ?,VUP
(n¼ 6 experiments). po0.05; po0.01.
Figure 4. Comparison between a-MSH and MSH 11^13 KP-D-Von
196b uveal melanoma invasion through ¢bronectin. Both peptides
signi¢cantly inhibited invasion (triplicate wells of cells were examined in
all cases), but no signi¢cant di¡erences between a-MSH (n¼ 5 experi-
ments) and KP-D-V (n¼ 4 experiments) were observed at the concen-
trations studied. Results are expressed as a mean percentage of the con-
trol7SEM. po0.05; po0.01.
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Ability of a-MSH and MSH 11^13 KP-D-V peptides to
oppose pro-invasive actions of TNF-a We then investigated
to what extent the anti-invasive action of the MSH peptides
could oppose the pro-invasive actions of TNF-a. Figure 5
summarizes results for all three uveal melanoma cell lines. For
all experiments, TNF-a at 200 units per mL was used, as this
concentration caused a maximum increase in invasion for all
three cell lines. a-MSH and KP-D-V were investigated at 109
M as this concentration was observed to maximally inhibit
invasion in the absence of TNF-a (Fig 3). For all cell lines, a-
MSH was added 15 min prior to TNF-a and melanoma cells
were exposed to TNF-a (with or without MSH peptides) for a
20 h invasion assay incubation. TNF-a was observed to increase
invasion for all three cell lines (Fig 5).When cells were exposed
to both TNF-a and a-MSH (109 M), the melanocortin peptide
signi¢cantly blocked the pro-invasive activity of TNF-a for two
of the three cell lines. Inhibition of TNF-a-stimulated invasion
was observed for the 177W7B7 cell line; however, this e¡ect did
not achieve statistical signi¢cance. KP-D-V (at 109 M) was
observed to signi¢cantly inhibit TNF-a-stimulated invasion for
all three uveal melanoma lines (Fig 5).
DISCUSSION
The aim of this study was to investigate whether iris melanomas
might di¡er in their metastatic potential compared with posterior
melanomas due to di¡erences in the local environment of
the anterior and posterior compartments. Clinical data shows a
10-fold better survival advantage for patients with melanoma of
the iris compared to patients with melanoma in the ciliary body
or choroid (McLean et al, 1982). Initially, we collected £uid from
the anterior and posterior compartments from patients with uveal
melanoma and studied the e¡ect of these £uids on the behavior
of established choroidal melanoma cell lines.We were unable to
extend this study to iridial melanoma cell lines due to the lower
frequency of occurrence of this tumor and the rarity of surgical
excision. Studies showed that £uid from the anterior chamber
signi¢cantly inhibited uveal melanoma invasion through ¢bro-
nectin by at least 50%. In contrast, vitreous £uid gave very
variable results and overall did not signi¢cantly in£uence the in-
vasive potential of the cells. These data support the hypothesis
that factors present in the aqueous £uid act to suppress melanoma
invasion. It was clear, however, that e¡orts to identify the factors
responsible would be challenging, as samples lost biologic activ-
ity through storage and sample volumes were always low. Never-
theless, previous studies have identi¢ed a range of anti-
in£ammatory factors present in aqueous £uid (Granstein et al,
1990; Jampel et al, 1990; Taylor et al, 1992; 1994; Knisely et al, 1994;
Apte and Niederkorn, 1996; Mochizuki et al, 2000), including the
anti-in£ammatory peptide a-MSH (Taylor et al, 1992) reported to
be present at 10^31 pM.
There are numerous reports of in£ammation in the eye leading
to the pathogenesis of uveitis; e.g., Franks et al (1992) have re-
ported TNF-a to be present in the vitreous at a concentration
range of 2^24 pg per ml.We report that the common proin£am-
matory cytokine TNF-a increased invasion of uveal melanoma
cell lines studied through a ¢bronectin monolayer. In addition,
we also found that the anti-in£ammatory peptide a-MSH de-
creased melanoma invasion. a-MSH also decreased the TNF-a-
stimulated increase in invasion.These ¢ndings are consistent with
an anti-in£ammatory/immunosuppressive environment in the
anterior chamber acting to reduce the metastatic behavior of
uveal melanoma cells. The lack of such factors in the posterior
compartment may be the basis of the di¡erent metastatic beha-
vior of such melanomas.
It has been reported previously that in£ammation enhances the
metastatic progression of several cancers including cutaneous
melanoma (Orosz et al, 1993; Hixson et al, 1994; Selinsky and
Howell, 2000;Vidal-Vanaclocha et al, 2000; Balkwill and Manto-
vani, 2001; Balkwill, 2002; Simiantonaki et al, 2002). In£amma-
tion is a very important component of normal wound healing,
as proin£ammatory cytokines increase cell migration and prolif-
eration and accelerate the process of wound healing.The presence
of tumor cells in an in£ammatory environment, however, could
feasibly lead to increased migration and tumor invasion. It has
Figure 5. E¡ect of TNF-a, a-MSH, and KP-D-Von uveal melano-
ma invasion. TNF-a (200 units per ml) increased invasion of all three
uveal melanoma cell lines, whereas a-MSH and KP-D-V (at 109 M) de-
creased invasion. The presence of a-MSH together with TNF-a signi¢-
cantly opposed the ability of the TNF-a to increase invasion in two out
of three cell lines. KP-D-V opposed the e¡ect of TNF-a in all three cell
lines. All experiments were conducted using triplicate wells of cells. Mean
values from these wells were compared to control untreated wells using
Student’s paired t test based on a minimum of three experiments. Values
di¡ering signi¢cantly from control values are indicated by po0.05,
po0.01, po0.001.Values di¡ering signi¢cantly fromTNF-a-stimu-
lated values are indicated by #po0.05, ##po0.01. The total number of
experiments is illustrated in each histogram and all data shown are normal-
ized with respect to the control value for ease of presentation.
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not been entirely resolved whether the immunosuppressive proper-
ties of the eye contribute towards increasing or decreasing metasta-
sis, with studies describing pro-metastatic (Repp et al, 2000) and low
metastatic (Filer et al, 1993) association. In the latter study Filer and
colleagues reported that out of 16 uveal melanoma tumors only one
had detectable levels of TNF-a. Interestingly, this tumor was taken
from only one of two patients who went on to develop metastasis.
The ability of melanocortins to act as anti-in£ammatory/im-
munomodulatory peptides has attracted interest in the last few
years (Star et al, 1995; Rajora et al, 1996; Catania et al, 1998; Lipton
and Catania, 1998; Chavatte et al, 2001; Getting, 2002). a-MSH
acts via the MC-1 receptor. Five melanocortin receptors have
been cloned to date (Mountjoy et al, 1992; Chhajlani et al, 1993)
and are expressed on a broad range of cells including keratino-
cytes, monocytes, neural cells, endothelial cells, and cutaneous
melanoma cells (Kippenberger et al, 1995; Luger et al, 2000;
Moustafa et al, 2002). In this study we show that all three uveal
melanoma lines express the MC-1R. The mechanism by which
a-MSH attenuates in£ammatory and immune responses is not
entirely understood (as it may act at more than one site). It is well
described as playing a central role in inhibiting the production
and/or action of proin£ammatory cytokines, e.g., IL-1b (Weiss
et al, 1991), IL-6 (Martin et al, 1991), and TNF-a (Hedley et al,
1998; Morandini et al, 1998), and increasing the synthesis of anti-
in£ammatory cytokines, e.g., IL-10 (Bhardwaj et al, 1996). Inhibi-
tion by a-MSH arises predominantly via an elevation of cyclic
AMP, and receptor-independent agonists (e.g., forskolin or iso-
butyl methyxanthine) that elevate intracellular cyclic AMP can
also mimic the actions of a-MSH. The minimum part of a-
MSH thought necessary to inhibit cytokine action is the MSH
11^13 tripeptide KPV.The mechanism by which the KPV peptide
works, however, has not been fully resolved either, with reports
suggesting that it may operate via a non-MC-1R route. This is
supported by work suggesting that an analogous MSH peptide
K-D-PV (referred to as an analog of IL-1b193^195) can act in
the manner of an IL-1b receptor antagonist, thereby blocking
the IL-1b proin£ammatory signal (Haddad et al, 2001).
Previous work from our group has shown that a-MSH can at-
tenuate TNF-a-stimulated upregulation of ICAM-1 in cutaneous
melanocytes and melanoma cells (Hedley et al, 1998; Morandini et
al, 1998) and, more recently, a and b integrins (Zhu et al, 2002). At
the intracellular level, we have reported that the peptide attenu-
ates TNF-a-stimulated activation of the transcription factor NF-
kB in uveal melanocytes, uveal melanoma cells, cutaneous mela-
noma (Haycock et al, 2000), and human keratinocytes (Moustafa
et al, 2002), with such e¡ects occurring by 12 h. Of particular
interest are reports that a-MSH is detectable in human aqueous
£uid (at 10^31 pmol) (Taylor et al, 1992). In this study we show
that concentrations as low as 1011 M can signi¢cantly inhibit in-
vasion for two of the three uveal melanoma cell lines. Thus, the
concentration of a-MSH in vitro is of the same order as that found
in vivo. The lack of high a⁄nity antisera capable of blocking a-
MSH activity presents an obstacle to investigating the potential
role of a-MSH in melanoma invasion.
a-MSH was investigated further using the minimum tripep-
tide sequence MSH 11^13 (KP-D-V) reported necessary for
inhibiting in£ammation. The presence of a D-valine moiety
(as opposed to L-valine) is suggested to convey greater potency
(Lipton and Catania, 1997). This was recently con¢rmed from this
laboratory for inhibition of TNF-a-stimulated activation of NF-
kB in a human keratinocyte cell line (Moustafa et al, 2002). In this
study we found that KP-D-Vwas equipotent with the full-length
a-MSH molecule at inhibiting uveal melanoma invasion through
¢bronectin. This o¡ers a possible approach to developing anti-in-
£ammatory peptides for reducing the metastatic properties of
uveal melanoma.
In summary, we have demonstrated that in£ammatory stress
caused byTNF-a signi¢cantly increases the invasiveness of uveal
melanoma cell lines, thus increasing the pro-metastatic biology of
these cells. Full-length a-MSH, at concentrations present in the
aqueous humor, as well as MSH 11^13 (KP-D-V) not only re-
duced the invasion of cells through human ¢bronectin but also
protected uveal melanoma cells from the pro-invasive actions of
TNF-a. Fresh aqueous humor (at 25%) signi¢cantly decreased
the invasion of uveal melanoma cells; in contrast, vitreous humor
at 25% did not reduce melanoma invasion. Taken together, these
results would be consistent with the hypothesis that the ocular
microenvironments play a major role in a¡ecting the metastatic
ability of uveal melanomas developing in the anterior or poster-
ior compartments of the eye. We suggest this hypothesis merits
further investigation because of the opportunities that it presents
to develop new approaches to reduce metastatic behavior of pos-
terior uveal melanoma.
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